Insulin-Like Growth Factor I
"Insulin-Like Growth Factor I" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A well-characterized basic peptide believed to be secreted by the liver and to circulate in the blood. It has growth-regulating, insulin-like, and mitogenic activities. This growth factor has a major, but not absolute, dependence on GROWTH HORMONE. It is believed to be mainly active in adults in contrast to INSULIN-LIKE GROWTH FACTOR II, which is a major fetal growth factor.
| Descriptor ID |
D007334
|
| MeSH Number(s) |
D12.644.276.937.400 D12.776.124.862.400 D12.776.467.937.400 D23.529.937.400
|
| Concept/Terms |
Insulin-Like Growth Factor I- Insulin-Like Growth Factor I
- Insulin-Like Somatomedin Peptide I
- Insulin Like Somatomedin Peptide I
- Somatomedin C
- IGF-I-SmC
- IGF-1
- IGF-I
- Insulin Like Growth Factor I
|
Below are MeSH descriptors whose meaning is more general than "Insulin-Like Growth Factor I".
Below are MeSH descriptors whose meaning is more specific than "Insulin-Like Growth Factor I".
This graph shows the total number of publications written about "Insulin-Like Growth Factor I" by people in this website by year, and whether "Insulin-Like Growth Factor I" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1996 | 3 | 0 | 3 |
| 2001 | 0 | 1 | 1 |
| 2003 | 1 | 0 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2008 | 2 | 0 | 2 |
| 2009 | 1 | 0 | 1 |
| 2010 | 2 | 1 | 3 |
| 2011 | 3 | 1 | 4 |
| 2012 | 2 | 0 | 2 |
| 2013 | 0 | 1 | 1 |
| 2014 | 3 | 0 | 3 |
| 2015 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
| 2024 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Insulin-Like Growth Factor I" by people in Profiles.
-
Skeletal consequences of preterm birth in pigs as a model for preterm infants. J Bone Miner Res. 2024 Jul 23; 39(6):791-803.
-
The MindMoves Trial: Cross-Sectional Analyses of Baseline Vascular Risk and Cognition in Older Women with Cardiovascular Disease. J Alzheimers Dis. 2024; 100(4):1407-1416.
-
The role of IGF-pathway biomarkers in determining risks, screening, and prognosis in lung cancer. Oncotarget. 2022; 13:393-407.
-
Safety, tolerability, and preliminary efficacy of an IGF-1 mimetic in patients with spinal and bulbar muscular atrophy: a randomised, placebo-controlled trial. Lancet Neurol. 2018 12; 17(12):1043-1052.
-
High fat-diet and saturated fatty acid palmitate inhibits IGF-1 function in chondrocytes. Osteoarthritis Cartilage. 2017 09; 25(9):1516-1521.
-
Impact of insulin-like growth factor 1 and insulin-like growth factor binding proteins on outcomes in acute myeloid leukemia. Leuk Lymphoma. 2015; 56(11):3135-42.
-
Effects of insulin-like growth factor-1 and dexamethasone on cytokine-challenged cartilage: relevance to post-traumatic osteoarthritis. Osteoarthritis Cartilage. 2015 Feb; 23(2):266-74.
-
Delivering heparin-binding insulin-like growth factor 1 with self-assembling peptide hydrogels. Tissue Eng Part A. 2015 Feb; 21(3-4):637-46.
-
Value of circulating insulin-like growth factor-associated proteins for the detection of stage I non-small cell lung cancer. J Thorac Cardiovasc Surg. 2015 Mar; 149(3):727-34.e1-3; discussion 734.
-
Aging and oxidative stress reduce the response of human articular chondrocytes to insulin-like growth factor 1 and osteogenic protein 1. Arthritis Rheumatol. 2014 Aug; 66(8):2201-9.